Metastatic Kidney Cancer
Conditions
Keywords
quality of life, cognitive functions, antiangiogenic agents, kidney cancer, metastatic
Brief summary
Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer
Interventions
None listed
Sponsors
Hoffmann-La Roche
Centre Francois Baclesse
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient (e) Age (e) over 18 years * Kidney cancer metastatic or locally advanced * Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together * Proposed treatment in first line or second line * Brain imaging not finding brain metastases * Having signed the informed consent of study participation * The patient may have received prior anti-angiogenic
Exclusion criteria
* Cancer of the kidney other than primitive * Previous history of cancer other than kidney cancer in complete remission for less than 5 years * Patients under 18 years * Patients whose treatment is associated with chemotherapy * disorders of cognitive functions to existing treatment delivery * Pathology psychiatric evolutionary * Refusal of participation * Patient unable to respond to cognitive tests * Drug use * Heavy drinking (WHO criteria) * History of stroke * History of head trauma * Brain metastases known * MMS below normal compared to existing standards for age and socio-cultural
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of fatigue, memory problems and attentional | up to 12 months after treatment | Assessing the impact of fatigue, memory problems and attentional induced by an anti-angiogenic and study their evolution over time in patients with metastatic kidney cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disorders of cognitive functions | up to 12 months after treatment | Studying the correlations between disorders of cognitive functions and parameters of quality of life and fatigue. |
| biological disturbances | up to 9 months after treatment | Search for biological disturbances may be related to fatigue and cognitive disorders. |
| Impact of anxiety and depression | up to 12 months after treatment | Assessing the impact of anxiety and depression at the waning of treatment |
| Parameters of quality of life | up to 12 months after treatment | Studying the different parameters of quality of life and their evolution over time. |
| Impact on the sexuality | up to 12 months after treatment | sess the impact on the sexuality of patients with the waning of treatment |
| Effects of different antiangiogenic agents | up to 12 months after treatment | Compare the impact on quality of life and cognition side effects of different antiangiogenic agents used |
| List of symptoms | up to 12 months after treatment | Compare the list of symptoms considered important by the patient compared to those recorded in the medical record. |
Countries
France
Outcome results
None listed